医药行业被称为“永远的朝阳产业”，主要原因在于其不断增长的市场需求。而推动中国医药行业市场需求增长的主要因素包括经济水平的增长、人们自我保健意识的增强，中国人口的老龄化和城镇化进程以及医疗体系改革的全面启动等，这些因素使得医疗消费的能力和意愿获得极大的提升，医药行业未来的需求将保持快速的增长。据IMS的预计，中国到2009年将成为世界第七大药品市场；到2020年，中国将成为仅次于美国的世界第二大药品市场，市场容量将达约2200亿美元。

　　根据国家统计局发布的最新数据，2008年1-5月，中国医药制造业实现销售收入2717.77亿元，同比增长26.63%。2007年全年，中国医药制造业实现产品销售收入5754亿元，同比增长21.5%，近10年的平均增速超过20%，远高于同期GDP的增速。而近2年医药制造业的利润增速还大大快于销售收入的增长，2007年前11个月，中国医药制造业实现利润总额499亿元，同比增长51.0%。2008年，全行业继续保持该增长势头，前5个月的行业利润达260亿元，同比增长41.4%。其中，国家的扶持和行业整顿起到了重要的作用。

图：2001-2008年中国医药制造业销售收入
 
来源：国家统计局，水清木华研究中心

　　受价格竞争、行业秩序混乱等诸多因素的影响，中国医药连锁业近4年来总体处于低迷状态。不过，在经过2006年的行业整顿和企业逐步提高自身的经营能力后，2007年的情况趋于好转。2007年，中国医药连锁业百强企业的净利润率平均达3%左右，高于2006年，利润额增幅更是达到56.2%，远高于销售增幅。

　　尽管我们对市场发展潜力的预期保持乐观，但由于医药连锁业近年来的扩张太快，在北京、上海、广州和深圳等主要城市，市场已经趋于饱和。成本上升、价格竞争及新医改等种种因素结合在一起，使中小药店的生存空间越来越窄。行业整合和集中的趋势逐渐明朗；对优势企业来说，这是难得的巩固自身市场地位的机会。

　　本报告依据中国国家统计局、卫生部、国家食品药品监督管理局、中国医药商业协会、中国药店网等权威渠道数据，部分重点企业数据主要来自公司年报和公司主页。

Pharmaceutical industry is called as “eternal sunrise industry”, mainly because of its sustained growth in market demand. The main factors driving the growth in market demand of China’s pharmaceutical industry include economic growth, improved people’s awareness of self-health care, the process of aging population and urbanization and full start-up of health system reform, which has greatly promoted the ability and willingness of medical consumption. China’s demand for medical industry in the future will maintain a rapid growth. According to the forecasts of IMS, China will become the seventh largest pharmaceutical market in the world in 2009 and will jump to the second largest one with a market capacity of US$220 billion after the U.S.A. in 2020

According to the latest statistics of the National Bureau of Statistics, the sales revenue of China’s pharmaceutical industry in the first five months of this year revenue reached CNY271.78 billion, up 26.63% year on year. In 2007, the sales revenue reached CNY575.4 billion, rising 21.5% year on year. The average growth rate of sales revenue of China’s pharmaceutical industry in the recent ten years exceeded 20%, far higher than GDP growth rate in the same period. Moreover, the profit growth rate of China’s pharmaceutical industry in the past two year was much higher than the growth rate of sales revenue. The total profit of China’s pharmaceutical industry in the first eleven months of 2007 reached CNY49.9 billion, jumping 51% year on year. In 2008, the industry continued maintaining the momentum of fast growth, and the total profit of the industry in the first five months of this year stood at CNY26 billion, 41.4% year on year, which is mainly attributed to government support and industry restructuring.

Sales Revenue of China Pharmaceutical Industry, 2001-2008

Source: ResearchInChina

Due to impact of many factors including mainly price competition and market disorder, China’s pharmaceutical chain industry was in the doldrums in the past four years in general. However, the industry had a turn for the better in 2007 after experiencing industry restructuring and gradually improved corporate operation in 2006. In 2007, net profit rate of China Top 100 pharmaceutical chain companies reached about 3%, higher than that in the previous year, and the growth rate of profit reached 56.2%, far higher than the growth rate of sales revenue.

Although we are optimistic about our forecast of potential of market development,
too fast expansion of pharmaceutical chain industry in large cities like Beijing, Shanghai, Guangzhou and Shenzhen has made market in these large cities tending to be saturated. Rising cost, price competition, new medical reform and other factors have made medium- and small-sized drugstores more and more difficult to survive. It is increasingly clear that China should further restructure its pharmaceutical chain industry to raise industrial concentration degree, which is a very good opportunity for those powerful companies to further strengthen their presence in the industry.  

The report is based on the authoritative statistics from the National Bureau of Statistics, the Ministry of Health, the State Food and Drug Administration, the China Association of Pharmaceutical Commerce and China Drugstore website as well as information from annual financial reports and websites of some key companies.

第一章 中国医药行业概述
1.1  中国医药行业产业链
1.2  中国医疗体系改革介绍
1.2.1  中国医改历程回顾
1.2.2  新医改的基本框架、目标和措施
1.3  中国医药行业发展的主要驱动因素
1.3.1  经济增长
1.3.2  人口老龄化
1.3.3  城市化进程
1.3.4  新医改的推动
1.3.5  居民医疗保健意识增强
1.3.6  技术进步
1.4  中国医药行业发展趋势预测

第二章 中国医药制造业运行状况分析
2.1  市场需求分析
2.1.1  总体规模
2.1.2  主要子行业
2.2  行业经济效益分析
2.2.1  总体经济效益
2.2.2  主要子行业效益

第三章 中国医药连锁业运行状况分析
3.1  行业主要指标分析
3.1.1  市场规模
3.1.2  盈利状况
3.1.3  其它指标
3.2  消费结构分析
3.3  药品价格走势分析
3.4  行业扩张情况分析
3.5  经营业态分析

第四章 中国医药连锁业竞争状况分析
4.1  市场集中度
4.2  行业竞争格局分析
4.3  中国医药连锁行业主要企业
4.3.1  总体规模比较
4.3.2  经济效益比较

第五章 中国医药连锁业重点区域分析
5.1  北京
5.2  上海
5.3  广东
5.4  江苏
5.5  湖南
5.6  辽宁
5.7  其它部分地区

第六章 中国医药连锁业发展趋势
6.1  市场趋势
6.2  消费结构发展趋势
6.3  药品价格趋势
6.4  竞争趋势
6.5  药店经营趋势
6.5.1  药店经营走进营销时代
6.5.2  传统药店转型
6.5.3  中小药店形成联盟
6.5.4  直营店回归
6.5.5  资本运作将成行业整合主要手段
6.6  重点关注领域
6.6.1  OTC药品市场
6.6.2  医保药品
6.6.3  药妆店

第七章 中国医药连锁业重点企业分析
7.1  老百姓大药房
7.1.1  公司概述
7.1.2  收入状况
7.1.3  连锁药店布局情况
7.2  海王星辰
7.2.1  公司概述
7.2.2  收入状况
7.2.3  连锁药店布局情况
7.3  湖北同济堂
7.3.1  公司概述
7.3.2  收入状况
7.3.3  连锁药店布局情况
7.4  重庆桐君阁大药房
7.4.1  公司概述
7.4.2  收入状况
7.4.3  连锁药店布局情况
7.5  国药控股国大药房
7.5.1  公司概述
7.5.2  收入状况
7.5.3  连锁药店布局情况
7.6  辽宁成大方圆
7.6.1  公司概述
7.6.2  收入状况
7.6.3  连锁药店布局情况
7.7  重庆和平药房
7.7.1  公司概述
7.7.2  收入状况
7.7.3  连锁药店布局情况
7.8  江西开心人
7.8.1  公司概述
7.8.2  收入状况
7.8.3  连锁药店布局情况
7.9  广东大参林
7.9.1  公司概述
7.9.2  收入状况
7.9.3  连锁药店布局情况
7.10  云南鸿翔药业有限公司（一心堂）
7.10.1  公司概述
7.10.2  收入状况
7.10.3  连锁药店布局情况
7.11  上海华氏大药房
7.11.1  公司概述
7.11.2  收入状况
7.11.3  连锁药店布局情况
7.12  湖南芝林
7.12.1  公司概述
7.12.2  收入状况
7.12.3  连锁药店布局情况
7.13  深圳中联大药房
7.13.1  公司概述
7.13.2  收入状况
7.13.3  连锁药店布局情况
7.14  沈阳东北大药房
7.14.1  公司概述
7.14.2  收入状况
7.14.3  连锁药店布局情况
7.15  北京金象大药房
7.15.1  公司概述
7.15.2  收入状况
7.15.3  连锁药店布局情况
7.16  同仁堂
7.17  贵州一树
7.18  美信（Medicine Shoppe）

1. Overview of China Pharmaceutical Chain Industry
1.1 Industrial Chain
1.2 China Medical System Reform
1.2.1 Reform Course Review
1.2.2 Basic Framework, Goals and Measures of the New Reform
1.3 Main Factors Driving China Pharmaceutical Industry Development
1.3.1 Economic Growth
1.3.2 Aging Population
1.3.3 Urbanization Process
1.3.4 Push from New Medical System Reform
1.3.5 Improvement in People’s Healthcare Awareness
1.3.6 Technology Improvement
1.4 Forecast of Development Trend

2. Operating Status of China Pharmaceutical Industry
2.1 Market Demand
2.1.1 General Size
2.1.2 Main Sub-industries
2.2 Economic Efficiency
2.2.1 Overall Economic Efficiencies
2.2.2 Economic Efficiencies of Main Sub-industries

3. Operating Status of China Pharmaceutical Chain Industry
3.1 Main Industry Indices
3.1.1 Market Size
3.1.2 Profitability
3.1.3 Other Indices
3.2 Consumption Structure
3.3  Price Trend
3.4  Industry Expansion
3.5  Business Mode

4. Competition Status of China Pharmaceutical Chain Industry
4.1 Market Concentration Degree
4.2 Competition Pattern
4.3 Key Enterprises
4.3.1 Comparison of Overall Sizes
4.3.2 Comparison of Economic Efficiencies

5. Key Regions of China Pharmaceutical Chain Industry
5.1 Beijing
5.2 Shanghai
5.3 Guangdong Province
5.4 Jiangsu Province
5.5 Hunan province
5.6 Liaoning Province
5.7 Other Regions

6. Development Trend of China Pharmaceutical Chain Industry
6.1 Market Trend
6.2 Development Trend of Consumption Structure
6.3 Price Trend
6.4 Competition Trend
6.5 Operation Trend
6.5.1 Marketing Era of Drugstore Management
6.5.2 Transformation of Traditional Drugstores
6.5.3 Alliances of Medium- and Small-Sized Drugstores
6.5.4 Return of Directly-Managed Drugstores
6.5.5 Capital Operation：A Major Means of Industry Integration
6.6 Key Concerns
6.6.1 OTC Drugs Market 
6.6.2 Medical Care Insurance Medicine
6.6.3 Drug Store Cosmetics

7. Key Companies of China Pharmaceutical Chain Industry
7.1 Laobaixing Drugstore
7.1.1 Company Profile
7.1.2 Revenue Status
7.1.3 Distribution of Chain Stores
7.2 Nepstar Drugstore
7.2.1 Company Profile
7.2.2 Revenue Status
7.2.3 Distribution of Chain Stores
7.3  Hubei Tongjitang Drugstore
7.3.1 Company Profile
7.3.2 Revenue Status
7.3.3 Distribution of Chain Stores
7.4 Chongqing Tongjunge Drugstore
7.4.1 Company Profile
7.4.2 Revenue Status
7.4.3 Distribution of Chain Stores
7.5 Guoda Drugstore of Sinopharm Medicine Holding Co.
7.5.1 Company Profile
7.5.2 Revenue Status
7.5.3 Distribution of Chain Stores
7.6 Liaoning Chengda Fangyuan Chain Drugstore
7.6.1 Company Profile
7.6.2 Revenue Status
7.6.3 Distribution of Chain Stores
7.7 Chongqing Heping Drugstore
7.7.1 Company Profile
7.7.2 Revenue Status
7.7.3 Distribution of Chain Stores
7.8 Jiangxi Kaixinren Drugstore
7.8.1 Company Profile
7.8.2 Revenue Status
7.8.3 Distribution of Chain Stores
7.9 Guangdong Dashenlin Drugstore
7.9.1 Company Profile
7.9.2 Revenue Status
7.9.3 Distribution of Chain Stores
7.10  Yunnan Hongxiang Pharmaceutical Co.(Yixintang Drugstore)
7.10.1 Company Profile
7.10.2 Revenue Status
7.10.3 Distribution of Chain Stores
7.11 Shanghai Huashi Drugstore
7.11.1 Company Profile
7.11.2 Revenue Status
7.11.3 Distribution of Chain Stores
7.12 Hunan Zhilin Drugstore
7.12.1 Company Profile
7.12.2 Revenue Status
7.12.3 Distribution of Chain Stores
7.13 Shenzhen Zhonglian Drugstore
7.13.1 Company Profile
7.13.2 Revenue Status
7.13.3 Distribution of Chain Stores
7.14 Shenyang Northeast Drugstore
7.14.1 Company Profile
7.14.2 Revenue Status
7.14.3 Distribution of Chain Stores
7.15 Beijing Jinxiang Drugstore
7.15.1 Company Profile
7.15.2 Revenue Status
7.15.3 Distribution of Chain Stores
7.16 Tongrentang Drugstore
7.17 Guizhou Yishu Drugstore
7.18 Medicine Shoppe